Abstract
Programmed cell death-1 (PD-1) and its ligands, particularly PD-L1 and PD-L2, are the most important proteins responsible for signaling T-cell inhibition and arbitrating immune homeostasis and tolerance mechanisms. However, the adaptive evolution of these genes is poorly understood. In this study, we aligned protein-coding genes from vertebrate species to evaluate positive selection constraints and evolution in the PD1, PD-L1 and PD-L2 genes conserved across up to 166 vertebrate species, with an average of 55 species per gene. We determined that although the positive selection was obvious, an average of 5.3% of codons underwent positive selection in the three genes across vertebrate lineages, and increased positive selection pressure was detected in both the Ig-like domains and transmembrane domains of the proteins. Moreover, the PD1, PD-L1 and PD-L2 genes were highly expressed in almost all tissues of the selected species indicating a distinct expression pattern in different tissues among most species. Our study reveals that adaptive selection plays a key role in the evolution of PD1 and its ligands in the majority of vertebrate species, which is in agreement with the contribution of these residues to the mechanisms of pathogen identification and coevolution in the complexity and novelties of vertebrate immune systems.
Highlights
The activation of mature peripheral B and T cells induces programmed cell death-1 (PD-1), a member of the CD28/CTLA-4 family [1, 2]
Our results revealed that positive selection acting on PD1, PD-L1 and PD-L2 genes drives adaptive changes for biological functions directly related to immunological tolerance in vertebrates
This study was designed to analyze the genomic sequences of programmed cell death-1 and its ligands in vertebrate species to calculate the selection pressure on these genes, which can contribute to adaptive evolution
Summary
The activation of mature peripheral B and T cells induces programmed cell death-1 (PD-1), a member of the CD28/CTLA-4 family [1, 2]. PD-L1 and PD-L2 ligation act as a secondary signal to T cells in combination with Tcell antigen receptor (TCR) signaling and results in the co-stimulation of a negative or inhibitory signal [5] that prevents the activation of TCR-mediated T cells and the production and proliferation of cytokines [6]. The expression of PD-L1 is observed on DCs, mast cells, T cells, B cells, macrophages, and nonhematopoietic cells, including astrocytes, vascular endothelial cells, keratinocytes, pancreatic islet cells, and corneal endothelial and epithelial cells. Both PD-L1 and PD-L2 are expressed on tumor stroma and tumor cells. The appearance of PD-L2 at tumor positions may contribute to T-cell restriction mediated by PD-1 [8]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.